Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)

Conditions

Pulmonary Hypertension

What is the purpose of this trial?

This study will investigate the effects of the combination of bosentan and sildenafil. Patients with symptomatic PAH treated with a stable dose of sildenafil equal to or greater tha 20 mg t.i.d. for at least 12 weeks will be randomized to placebo or bosentan 125 mg b.i.d. All randomized patients will be treated with study drug until the predefined target number of morbidity/mortality events is reached.



Participation Guidelines

Age:
12 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Actelion
Dates:
April 2006
Last Updated:
February 17, 2012
Study HIC#:
0601000965

Clinicaltrials.gov ID: NCT00303459